Literature DB >> 4027136

Ranitidine does not alter pethidine disposition in man.

D R Guay, R C Meatherall, J L Chalmers, G R Grahame, R J Hudson.   

Abstract

The effect of concurrent ranitidine administration on the disposition of pethidine was investigated in eight healthy male volunteers (19-33 years). The subjects received 70 mg i.v. pethidine HCl doses before and during ranitidine treatment (150 mg p.o. twice daily). Ranitidine therapy was not associated with significant alterations in pethidine elimination rate constant, volume of distribution at steady state, total body clearance, and 24 h urinary excretion. No alteration in pethidine oxidation to norpethidine was noted, as suggested by nonsignificant changes in lag time to appearance of quantifiable norpethidine in serum, time to peak concentration, peak concentration, area under the curve from time 0.24 h, and 24 h urinary excretion. It would appear that, unlike cimetidine, ranitidine does not interact pharmacokinetically with pethidine. Further studies are necessary to evaluate the potential clinical advantages of ranitidine vs cimetidine therapy in patients also receiving pethidine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027136      PMCID: PMC1400623          DOI: 10.1111/j.1365-2125.1985.tb02798.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Pharmacokinetics of drug disposition: hemodynamic considerations.

Authors:  G R Wilkinson
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

2.  H2-receptor antagonists and hepatic drug disposition.

Authors:  G W Mihaly; R A Smallwood; J D Anderson; D B Jones; L K Webster; F J Vajda
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

3.  Interaction of H2-receptor antagonists with drug-metabolizing enzymes.

Authors:  J A Bell; A J Gower; L E Martin; E N Mills; W P Smith
Journal:  Biochem Soc Trans       Date:  1981-02       Impact factor: 5.407

Review 4.  Ranitidine: a new H2-receptor antagonist.

Authors:  J B Zeldis; L S Friedman; K J Isselbacher
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

5.  Analysis of meperidine and normeperidine in serum and urine by high-performance liquid chromatography.

Authors:  R C Meatherall; D R Guay; J L Chalmers
Journal:  J Chromatogr       Date:  1985-02-27

6.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

Review 7.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

8.  Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.

Authors:  C A Helman; L O Tim
Journal:  Pharmacotherapy       Date:  1983 Jul-Aug       Impact factor: 4.705

9.  Cimetidine alters pethidine disposition in man.

Authors:  D R Guay; R C Meatherall; J L Chalmers; G R Grahame
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 10.  Ranitidine hydrochloride.

Authors:  T S Gaginella; J H Bauman
Journal:  Drug Intell Clin Pharm       Date:  1983-12
View more
  5 in total

1.  [Not Available].

Authors:  P Löhmer; W Tolksdorf
Journal:  Schmerz       Date:  1989-03       Impact factor: 1.107

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 4.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 5.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.